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Abstract: 16K prolactin (PRL) is the name given to the 16-kDa N-terminal fragment obtained by proteolysis of 
rat PRL by tissue extracts or cell lysates, in which cathepsin D was identified as the candidate protease. Based on 
its antiangiogenic activity, 16K PRL is potentially a physiological inhibitor of tumor growth. Full-length human 
PRL (hPRL) was reported to be resistant to cathepsin D, suggesting that antiangiogenic 16K PRL may be 
physiologically irrelevant in humans. In this study, we show that hPRL can be cleaved by cathepsin D or 
mammary cell extracts under the same conditions as described earlier for rat PRL, although with lower 
efficiency. In contrast to the rat hormone, hPRL proteolysis generates three 16K-like fragments, which were 
identified by N-terminal sequencing and mass spectrometry as corresponding to amino acids 1-132 (15 kDa), 1-
147 (16.5 kDa), and 1-150 (17 kDa). Biochemical and mutagenetic studies showed that the species-specific 
digestion pattern is due to subtle differences in primary and tertiary structures of rat and human hormones. The 
antiangiogenic activity of N-terminal hPRL fragments was assessed by the inhibition of growth factor-induced 
thymidine uptake and MAPK activation in bovine umbilical endothelial cells. Finally, an N-terminal hPRL 
fragment comigrating with the proteolytic 17-kDa fragment was identified in human pituitary adenomas, 
suggesting that the physiological relevance of antiangiogenic N-terminal hPRL fragments needs to be 
reevaluated in humans. 
Abbreviations: bFGF, Basic fibroblast growth factor; BUVEC, bovine umbilical vein endothelial cells; FCS, 
fetal calf serum; GRO, growth-related oncogene; hPRL, human PRL; mAb, monoclonal antibody; MALDI-TOF, 
matrix-assisted laser desorption/ionization time-of-flight; MCP, monocyte chemotactic protein; PRL, prolactin; 
16K PRL, 16-kDa fragment of PRL; rPRL, rat PRL; TIMP, tissue inhibitor of metalloproteinase; VEGF, 
vascular endothelial growth factor; WT, wild-type. 
 
INTRODUCTION 
THE NAME 16 K PROLACTIN (PRL) was given 15 yr ago to the 16-kDa fragment resulting from the in vitro 
proteolysis of full-length rat PRL (rPRL) (23 kDa) by cell lysates or tissue extracts (e.g. 25,000 x g pellet of rat 
mammary gland) under acidic conditions (1, 2). Purified 16K rPRL was subsequently demonstrated to exert 
antiangiogenic properties in various in vitro and in vivo models (3), which confers potential antitumor potency to 
this polypeptide. These findings have considerably increased the interest of the scientific community for 16K 
PRL, and several investigations have been performed since its discovery to elucidate the molecular mechanisms 
underlying its interesting biological properties. 
The generation of rat 16K PRL in vitro requires two steps (2). First, efficient proteolysis requires acidic pH (<4), 
in agreement with the fact that the candidate protease involved, cathepsin D (4), is an acidic protease. Two 
cleavage sites were identified in rPRL, following residues 145 and 148 (4, 5). Because all PRLs contain an 
internal disulfide bond between cysteines 56 and 172 (rat sequence numbering) (6), the proteolysis step generates 
so-called cleaved PRL, a PRL isoform in which N-terminal 16-kDa (residues 1-145) and C-terminal 7-kDa 
(residues 149-197) fragments remain covalently linked. The release of the 16-kDa fragment thus requires a 
second step, i.e. the reduction of cleaved PRL (Fig. 1). To circumvent the difficulties linked to the purification of 
16K PRL from PRL proteolysed by tissue extracts, 16K PRL was subsequently produced by recombinant 
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technology using the human PRL (hPRL) sequence. Several versions of recombinant 16K-like hPRL were 
generated depending on the position of the engineered stop codon inserted within the hPRL cDNA sequence (7). 
Recombinant hPRL fragments encompassing sequences 1-124 (8) and 1-139 and 1-142 (9) were engineered, and 
all of these were shown to display antiangiogenic properties similar to those reported for rat 16K PRL in various 
bioassays. Using the 1-139 hPRL fragment, some of the molecular mechanisms underlying the antiangiogenic 
activity of N-terminal PRL fragments were determined. For example, 16K PRL was shown to inhibit the 
mitogenic activity of vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) on 
endothelial cells, an effect involving the inhibition of signaling pathways triggered by these angiogenic factors 
(10, 11). In addition to this inhibitory action of growth factors, 16K PRL intrinsically induces apoptosis by 
activating the caspase pathway via nuclear factor ΚB (12,13) and the expression of plasminogen activator 
inhibitor-1, a specific inhibitor of urokinase that activates proteases involved in endothelial cell migration and 
tissue remodeling (14). All these effects are presumably mediated by a membrane receptor that differs from the 
classical PRL receptor, but remains to be identified (15). 
Based on its antiangiogenic properties, 16K PRL appears to be a new candidate in the wide spectrum of 
antitumor drugs. But maybe more importantly, because full-length (23K) and 16K PRLs were recently proposed 
to have opposing actions on angiogenesis in experimental models (the former stimulates, the latter inhibits) (9), 
the possibility exists that their respective ratio may participate in the physiological regulation of angiogenesis in 
vivo, especially in the context of PRL-secreting tumors (16). In addition, because full-length PRL exerts 
proliferative actions in various models of breast tumors (17), the existence of antiangiogenic N-terminal 16K-
like fragments of hPRL that may balance the effect of PRL on tumor growth in vivo is a question that deserves 
further investigation. Several years ago, one of us reported that very little specific cleavage products could be 
obtained after incubation of hPRL with mammary subcellular fractions (2). In good agreement, the group of 
Ben-Jonathan (18) reported in 1999 that hPRL was resistant to cleavage by cathepsin D or mammary cell 
extracts at acidic pH. In contrast, these authors showed that thrombin can process hPRL at physiological pH into 
a 16-kDa fragment, but the latter was identified as the C-terminal end of the hormone (sequence 54-199) and was 
shown to be devoid of any angiostatic properties (18). Based on that study, any human homolog to the 
antiangiogenic 16-kDa fragment obtained with rPRL wou Id be irrelevant. 
Closer analysis of the data provided by Ben-Jonathan and colleagues prompted us to reevaluate the proteolysis of 
hPRL into N-terminal 16K-like fragments. The present study is the first report showing the ability of hPRL to be 
cleaved by normal and tumor mammary cell extracts into a pattern of multiple fragments, specific to the human 
species and distinct from the pattern observed with the rat hormone. At least four cleavage sites by the acidic 
protease cathepsin D were identified within hPRL sequence, three of which generate N-terminal 16K-like 
fragments that all display antiangiogenic activity. These observations clearly renew the interest for studying the 
potential relevance of antiangiogenic 16K-like PRL in human species. 
RESULTS 
The Pattern of PRL Fragments Generated by Human Breast Cells Is Species Specific 
Many tissue extracts, including mammary gland, liver, or prostate, were previously shown to process rPRL into 
16K PRL in acidic conditions (19); therefore we used mammary epithelial cells to study the proteolysis of hPRL 
Electrophoresis under reducing conditions reveals that acidified T-47Dco cell lysates cleave hPRL into multiple 
fragments the apparent molecular masses of which were estimated to be approximately 17, 15, and 11 kDa based 
on their electrophoretic mobility, the two larger clearly differing in size from the formerly described 16K rPRL 
(Fig. 1A, right panel). Smaller fragments of approximately 8 and 5 kDa could also be seen, although their size 
made detection more difficult (data not shown). Electrophoresis under non-reducing conditions (Fig. 1A, left 
panel) indicates that rat and human PRL fragments remain linked by intramolecular disulfide bonds because only 
intact oxidized PRL (23 kDa) and slower migrating cleaved form(s) of PRL were detected, the latter appearing as 
a single band (rat) or as a doublet (human). These observations confirm pioneering experiments investigating 
hPRL proteolysis by subcellular fractions of mammary gland (2). 
The various bands detected in Coomassie blue staining were clearly identified as hPRL fragments by 
immunoblotting with the anti-hPRL monoclonal antibody (mAb) (6E4) directed against recombinant 16K hPRL 
(Fig. 1B). In certain experiments, the larger band (referred to as 17K PRL) detected by Coomassie blue staining 
appeared to contain two immunoreactive bands corresponding to molecular masses of approximately 16.5/17 
kDa (Fig. 1B). Because of almost identical electrophoretic mobilities, these two fragments frequently focused as 
a single band. A similar pattern of hPRL fragments, with 17- and 15-kDa fragments predominantly detected, was 
obtained when hPRL was digested using conditioned medium obtained from T47Dco cultures (Fig. 1C), 
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indicating that the protease involved is secreted by the cells. Proteolysis occurred only in acidic conditions, 
suggesting the involvement of an acidic protease. The absence of cleavage when using heated conditioned 
medium (Fig. 1C) or cell lysates (data not shown) demonstrates that hPRL does not undergo spontaneous 
degradation during the assay. Finally, 17-kDa and, to a much lesser extent, 15-kDa fragments comigrating with 
those generated using T47Dco lysates (data not shown) were also obtained when digestion was performed using 
acidified tissue homogenates from human breast biopsies, obtained from either normal or tumor tissue (Fig. 1D). 
Although the cleavage efficiency differed from one breast biopsy to another, the number of samples available for 
these preliminary studies was insufficient to state that the proteolytic efficiency is related to the 
pathophysiological status of the tissue (tumor vs. normal). However, this experiment indicates that hPRL 
proteolysis is not limited to the T47Dco cell line. 
Taken together, our data are in good agreement with one of our previous reports (2) and indicate that 1) hPRL 
can be processed into several fragments by an acidic protease expressed in mammary cells and se- 
creted into the extracellular space, and 2) the proteolytic pattern is specific to the human hormone and distinct 
from the well-known 16K rPRL. 
 
Fig. 1: Cleavage of hPRL by Human Mammary Cell Lysates or Conditioned Medium  
Rat and human PRL were digested in various conditions (as indicated) by T47Dco cell lysates (A and B), T47Dco conditioned medium (C), 
or cell extracts of tumor and normal human breast (D). All SDS-PAGE gels were run under reducing conditions, except in left panel A, and 
immunoblots were performed using monoclonal anti-hPRL 6E4. cl-PRLs, Cleaved PRLs 
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The Candidate Protease Involved in hPRL Cleavage Is Cathepsin D 
We then tried to identify the protease involved, first by using various protease inhibitors. Cleavage of hPRL by 
T-47Dco conditioned medium was inhibited in the presence of pepstatin or EDTA, but not of the other inhibitors 
tested (Fig. 2A). Because pepstatin in known to inhibit cathepsin D, the involvement of this protease in hPRL 
cleavage was further examined, although it was claimed that hPRL is resistant to cathepsin D (18). First, 
incubation of acidified T-47Dco conditioned medium with a neutralizing anticathepsin D antibody before 
addition of hPRL prevents any proteolysis, strongly supporting the pivotal role of this protease in the cleavage 
(Fig. 2B). Second, the pattern of hPRL fragments generated by purified human cathepsin D appears to be 
virtually identical to that obtained using T47Dco cell lysates (Fig. 2C), i.e. characteristic of human species (see 
Fig. 1). The proteolytic profile of pituitary-purified hPRL was found to be identical to that obtained with 
recombinant PRL, demonstrating that the present findings are not due to the fact that we use bacterially produced 
hPRL for the proteolysis studies (Fig. 2D). Finally, hPRL proteolysis performed using thrombin (Fig. 2E), a 
protease that was shown to process hPRL into a C-terminal 16-kDa fragment (18), unequivocally demonstrated 
that none of the 15- to 17-kDa fragments generated by cathepsin D match the C-terminal 16K hPRL 
Taken together, these results indicate that 1) under acidic conditions, the aspartyl protease cathepsin D is able to 
cleave hPRL into several fragments distinct from the well-characterized 16K rPRL, and 2) this protease is the 
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candidate protease responsible for hPRL processing by mammary cell extracts or conditioned media. 
Composition of hPRL Fragments 
The composition of hPRL fragments was determined using three complementary approaches: proteolysis 
experiments using N-terminal-deleted hPRL mutants, N-terminal sequencing, and mass spectrometry. When 
hPRL analogs lacking the nine or 14 N-terminal residues (20) were used for cathepsin D-mediated proteolysis, 
the electrophoretic mobility of the four larger bands (17, 16.5, 15, and 11 kDa) was accelerated, suggesting they 
are indeed N-terminal fragments (data not shown). In a second experiment, hPRL was digested using T47Dco 
cell lysates or purified cathepsin D, and immunoreactive bands were recovered from anti-hPRL immunoblots for 
N-terminal sequencing analysis. The 17K/16.5K (not separated) and 15K peptides share the same N-terminal 
sequence as undigested recombinant hPRL (with the additional initiation methionine) (21), confirming that they 
correspond to N-terminal fragments (Fig. 3A). Identical N-terminal sequences were obtained for cognate hPRL 
fragments resulting from digestion by mammary cell lysates or by purified cathepsin D, strengthening the 
likelihood that the latter is the cellular protease involved. The 8-kDa and 5-kDa fragments start at residues Ile133 
and Ser151, respectively, suggesting they may be complementary to 15K and 16.5K/17K hPRL The 11-kDa 
fragment appeared to contain more than a single peptide, because signals starting at residue 1 and Ile87 were 
detected. A minor signal starting at Phe37 was also detected within the 8-kDa band. 
To determine the exact composition of these hPRL fragments, we performed matrix-assisted laser 
desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry analysis using a solution of hPRL 
digested by cathepsin D. All analyses were performed in parallel using two hPRL analogs the molecular mass of 
which differs from that of WT hPRL, namely ∆1-9-hPRL (lacking residues 1-9) (20) and G129R-hPRL (Arg 
substituted for Gly129) (22). To unambiguously distinguish peaks corresponding to hPRL fragments from 
background, we compared digested hPRL (WT and analogs) before and after reduction, because release of 
proteolytic fragment only occurs under reducing conditions (see Introduction). The experimental data of PRL-
related ion peaks and the theoretical molecular weights corresponding to the candidate sequences are reported in 
Table 1. Based on their molecular masses, the three peaks detected in the 15- to 17-kDa range after proteolysis of 
WT hPRL (Fig. 3B) were assigned to sequences 1-132, 1-147, and 1-150, in perfect agreement with the fact that 
corresponding peaks were all shifted toward smaller masses (by ~800 Da) when proteolysis involved the ∆1-9-
hPRL analog, and toward higher masses (by ~100 Da) when proteolysis involved G129R-hPRL (Table 1). Two 
other peaks (5.7 and 7.9 kDa) remained unchanged whether proteolysis was performed using WT hPRL, ∆1-9-
hPRL, or G129R-hPRL, indicating they correspond to C-terminal sequences that could be assigned to fragments 
133-199 and 151-199, respectively. Finally, two clusters of peaks assigned to sequences 1-80, 1-84, and 1-85 for 
the first, and 85-199, 88-199, and 90-199 for the second were also detected in the 9- and 13-kDa regions of the 
spectra, respectively (data not shown). In agreement with the sequences assigned, the first cluster was shifted to 
smaller masses for ∆1-9-hPRL but remained unchanged for G129R-hPRL, whereas it was the opposite for the 
second cluster. These fragments presumably result from initial cleavage around residue 85 and subsequent 
aminopeptidase and carboxypeptidase activities. 
Fig. 2: The Mammary Protease Involved in hPRL Cleavage Is Cathepsin D 
Proteolysis of hPRL was performed by conditioned medium or cell lysates of T-47Dco, or purified proteases as indicated in Materials and 
Methods. A, Among the various protease inhibitors tested, only EDTA and pepstatin inhibit proteolysis by conditioned medium. B, 
Immunodepletion of conditioned medium by anticathepsin D antibody (8 µg/ml) prevents hPRL cleavage. C, Proteolysis of hPRL by T-
47Dco lysates or purified human cathepsin D generates a similar pattern of hPRL fragments. D, The proteolytic pattern obtained with 
cathepsin D is identical whether recombinant or pituitary-purified hPRL is used. E, The proteolytic patterns of hPRL resulting from digestion 
by cathepsin D and thrombin are different. 
Published in: Molecular Endocrinology (2004), vol. 18, iss. 10, pp. 2522-2542 6 
Status: Postprint (Author’s version) 
 
Taken together, these results obtained by in vitro proteolysis of hPRL analogs, N-terminal sequencing, and mass 
spectrometry analyses indicate that hPRL contains at least four cleavage sites for cathepsin D (Fig. 3, C and D). 
The three sites generating 16K-like N-terminal fragments are unambiguously located between residues 132-133, 
147-148, and 150-151. The location of the fourth site is less clear and is presumably located near residue 85. 
 
Fig. 3: Composition of hPRL Fragments Generated by Human Breast Cells 
A, hPRL fragments generated by T-47Dco lysates or purified cathepsin D (see Fig. 2C) were sequenced at their N-terminal end (the initiation 
methionine of recombinant hPRL is omitted for clarity). Corresponding fragments in both digestion have identical N termini. Minor 
sequences were obtained for the 11- and 8-kDa bands (see Results). B, Mass spectrometry analysis of hPRL was performed before (upper 
panels) and after (lower panels) reduction. Only the data corresponding to the three N-terminal 15- to 17K fragments are shown. The peaks 
appearing in reduced samples correspond to hPRL fragments released from cleaved hPRL. C indicates the peak of the calibrant. C, 
Schematic representation of the four cleavage sites for cathepsin D in hPRL, as deduced from N-terminal sequencing and mass spectrometry. 
D, As recently confirmed by NMR (41), hPRL adopts the four-helix bundle folding (helices are numbered 1-4). The four cathepsin D 
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cleavage sites that we identified in this study are located in the same region of the folded protein (dotted circle). For each site, the main chain 
atoms of the amino acids before and after the cleavage are represented (red, oxygen; light blue, carbon; dark blue, nitrogen). 
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Figure 3: Continued 
 
 
Table 1: Theoretical and Experimental Molecular Weights (mw) of hPRL Fragments Identified by Mass 
Spectrometry 
WT hPRL ∆1-9 hPRL G129R-hPRL Sequence 
Theoretical mw Exp. MH+ Theoretical mw Exp MH+ Theoretical mw Exp MH+ 
Full length 23,029.3 23,028 ± 3 22,233.4 22,238 ± 5 23,128.5 23,127 ± 3 
1-132 15,136.3 15,138 ± 3 14,340.3 14,342 ± 4 15,235.4 15,235 ± 3 
1-147 16,904.3 16,907 ± 3 16,108.3 Not observed 17,003.4 Not observed 
1-150 17,286.7 17,289 ± 3 16,490.7 16,510 ± 4 17,385.9 Not observed 
133-199 7,911.0 7,914 ± 3 7,911.0 7,913 ± 3 7,911.0 7,914 ±2 
151-199 5,760.6 5,766 ± 3 5,760.6 5,763 ± 3 5,760.6 5,764 ± 3 
The experimental value refers to the average mass of the protonated molecules of protein and fragments. Exp, Experiment. 
 
Species Specificity of PRL Proteolytic Pattern 
We next addressed the question whether the specific characteristics of hPRL proteolysis (cleavage efficiency and 
fragment pattern) could be correlated to any intrinsic features of its primary structure. Interestingly, alignment 
between rat and human sequences shows that the two cleavage sites identified in the rat hormone (4, 5) are 
topologically equivalent to those generating 16.5K and 17K hPRL (Fig. 4A), with release of a tripeptide 
corresponding to residues 146-148 in the rat and 148-150 in the human hormone. This indicates that 16.5K hPRL 
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is homologous to 16K rPRL, whereas 15K hPRL has no equivalent in the rat hormone. Two cathepsin D 
recognition sites within hPRL show major differences with the rat sequence, namely Lys131 (rat)/Leu133 (human) 
substitution in the first one, and Leu146 (rat)/Pro148 (human) substitution in the second (Fig. 4A). Four PRL 
mutants containing single amino acid substitutions at these positions were produced and analyzed (hPRL L132K, 
hPRL P148L, hPRL P148A and rPRL P146L). All analogs maintained full bioactivity in a hPRL receptor-
mediated bioassay (23), suggesting that the mutations did not significantly affect protein folding (data not 
shown). Substitution of Leu (Fig. 4B, left panel) or Ala (data not shown) for Pro148 in hPRL dramatically 
increases proteolysis efficiency, because almost 90% of full-length hormone disappeared after 3 h of in vitro 
enzymatic reaction [there was no spontaneous degradation in the absence of enzyme (data not shown)]. In 
contrast, substitution of Pro for Leu146 in rPRL had the opposite effect, because a significant amount of full-
length hormone remained undigested after 3 h (Fig. 4B, right panel). This clearly indicates that a proline residue 
at position 148 (naturally occurring in hPRL) is detrimental to high cleavage efficiency, whereas a Leu (naturally 
occurring in rPRL) is not mandatory. In addition, the Pro-Leu substitution also modifies the proteolytic pattern. 
In rPRL, only the 16.5K fragment resulting from cleavage at the 148-149 site is detected (Fig. 4B, right), 
indicating that the other cleavage site (145-146) is rendered nonfunctional by the proline substitution. As would 
be expected, because removal of Pro148 in hPRL renders the 147-148 site highly functional, this leads to the 
preferential formation of 16.5K hPRL and the complementary 5K fragment (Fig. 4B). With respect to the 132-
133 recognition site, substitution of a Lys for Leu132 in hPRL abolishes the cleavage, as deduced from the 
absence of the 15K fragment (Fig. 4B), which suggests that a lysine residue at this position (as naturally 
occurring in rPRL) is detrimental to cathepsin D cleavage. 
These data indicate that the specific features of hPRL proteolysis are directly linked to the presence of two key 
residues in its sequence: Pro148 prevents high cleavage efficiency at 147-148 and 150-151 sites, and Leu132, in 
contrast, is responsible for the additional cleavage at site 132-133. 
 
Fig. 4: Site-Directed Mutagenesis in Cathepsin D Cleavage Sites 
A, Comparison of primary structures of rat and human PRL around the three cleavage sites generating 16K-like N-terminal fragments. The 
two major differences are boxed. B, In vitro proteolysis of human and rat PRL analogs mutated within cleavage sites. Point mutations at 
positions corresponding to Pro148 and Leu132 markedly modify the proteolytic pattern of both PRLs. 
 
Published in: Molecular Endocrinology (2004), vol. 18, iss. 10, pp. 2522-2542 10 
Status: Postprint (Author’s version) 
Efficiency of hPRL Proteolysis by Cathepsin D 
We next investigated whether the moderate in vitro cleavage efficiency of hPRL was somehow linked to partly 
inappropriate experimental conditions of proteolysis. Although increasing the duration or the temperature of the 
enzymatic reaction led to the rapid disappearance of full-length hPRL (Fig. 5A, left), this failed to result in 
concomitant accumulation of proteolytic fragments, suggesting that these experimental conditions favor 
degradation rather than specific proteolysis. This phenomenon was not observed using rPRL (data not shown), 
suggesting it is hPRL specific. As would be expected, optimal proteolysis was observed between pH 3 and pH 
4.5, and pH above 5.5 failed to generate any fragment (Fig. 5B). 
To investigate whether some features of hPRL conformation could also participate in the moderate efficiency of 
cathepsin D cleavage, the proteolysis was performed in medium containing low concentrations of Triton X-100, 
with the goal of slightly relaxing the hormone structure (Fig. 5C). Interestingly, very low concentrations (0.01%) 
of detergent strongly increased cleavage efficiency (room temperature), and 0.05% Triton was sufficient to 
obtain near-complete proteolysis of hPRL with concomitant accumulation of proteolytic fragments. Because 
0.05% Triton X-100 was detrimental to the cleavage of rPRL (data not shown), this suggests that at this 
concentration, the detergent modifies the folding of the hormone rather than increasing enzyme activity. 
Detergent concentrations above 0.1% were detrimental to hPRL proteolysis, presumably by affecting folding of 
the protease itself. In contrast to proteolysis performed at 37 C, which favors hPRL degradation (Fig. 5A), Triton 
X-100 led to the accumulation of 15K and 8K fragments. When the same experiment was performed using ∆1-9-
hPRL analog, a slightly smaller fragment (~14 kDa) was obtained in place of the 15-kDa fragment observed after 
WT hPRL proteolysis (Fig. 5C), strongly suggesting that the detergent favors proteolysis at the 132-133 site, 
resulting in the generation of the N-terminal 15K fragment. 
These experiments show that relaxing hPRL conformation using very low concentrations of Triton X-100 
dramatically increases hormone processing at the 132-133 site. 
 
Fig. 5: Efficiency of hPRL Proteolysis by Cathepsin D 
A, Time course proteolysis of hPRL by cathepsin D at room temperature and 37 C. B, Efficiency of hPRL proteolysis over a 3-7 range of pH. 
C, Effect of various concentrations of Triton X-100 on proteolysis. Low concentration of the detergent (0.05%) enhances proteolysis without 
changing cleavage specificity, as demonstrated by the profile obtained for ∆1-9-hPRL. All SDS-PAGE were run under reducing conditions 
and gels were revealed using Coomassie blue staining. 
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Fig. 6: Expression of 15-17K hPRL Fragments in COS-7 Cells 
A, COS-7 cells were transfected with the indicated expression vectors, and conditioned media were harvested 24 h after transfection. The 
electrophoretic mobility of the various fragments under reducing conditions is correlated to their length. The arrow indicates the presence of 
a 16K-like fragment in conditioned medium from cells transfected with the expression plasmid of full-length hPRL. B, All fragments are 
expressed as three bands (arrows), two of which correspond to glycosylated isoforms because a single band is obtained after treatment with 
glycosidase F. C, COS-7 cells secrete angiogenesis-related factors, some of which were identified using an angiogenesis antibody array (each 
antibody is spotted in duplicate). Left panel represents the negative control, obtained after incubation of the membrane array with 
DMEM/0.1% BSA. Spots A1, A2, and D8 are positive controls of the enhanced chemiluminescence reaction. Two angiogenesis-related 
factors were detected in fresh DMEM/0.1% BSA: IL-6 (B4), and TGFβ (C3), which probably result from small growth factor contamination 
in BSA (98% purity). Right panel shows a membrane that was incubated in DMEM/0.1 % BSA conditioned for 24 h with COS-7 cells. Five 
additional spots were detected, which correspond to bFGF (A8), GRO (B1), MCP-1 (B7), TIMP-2 (C5), and VEGF (C7) (see text). 
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Production of Recombinant N-Terminal Fragments of hPRL 
The next step of our investigations was to characterize the biological properties of the hPRL fragments 
identified. Due to both the moderate efficiency of hPRL cleavage in the absence of detergent and the physi-
cochemical similarity of the three N-terminal hPRL fragments (size, charge), they could not be separated by 
standard chromatography. In addition, because chromatography steps are known to represent a potential source 
of endotoxin contamination (12), working with purified hormone can paradoxically be detrimental to the 
reliability of the results obtained in angiogenesis assays if the endotoxin issue is not under control. Therefore, we 
decided to produce recombinant hPRL fragments by transiently transfecting COS-7 cells, and then to stimulate 
endothelial cells directly with COS-7 cell-conditioned media, without any purification, to eliminate the risks of 
endotoxin contamination. This strategy has been successfully used in the past by us and others for similar 
purposes (24, 25). 
To produce 15K, 16.5K, and 17K hPRL with a sequence strictly identical to that of the fragments generated by 
cathepsin D proteolysis and identified by mass spectrometry (Fig. 3B), a stop codon was inserted into the hPRL 
cDNA sequence at position 133, 148, or 151. To limit covalent oligomerization, we also produced the same 
fragments in which a Ser was substituted for free Cys58, which normally forms an intramolecular disulfide bond 
with Cys174 in full-length hPRL. As the positive control for bioassays, we produced in the same cell system the 
hPRL fragment encompassing residues 1-139 because this recombinant 16K hPRL construct was previously 
shown to exert antiangiogenic activity in various in vitro and in vivo bioassays (9,13, 25). As the negative 
controls, we transfected COS-7 cells with parental pc-DNA3.1 vector (mock transfection) or full-length hPRL 
vector, because hPRL is not expected to exert antiangiogenic activity. 
hPRL fragments are expressed and secreted into the medium of transiently transfected COS-7 cells (Fig. 6A), 
and the absence of any immunoreactive band in conditioned medium of mock transfected cells (data not shown) 
confirmed that the bands detected are PRL related. As previously reported (26), N-terminal fragments were 
expressed in this system as two or three bands of different mobility. We demonstrated that the slower bands 
correspond to glycosylated iso-forms because a single band was obtained after analytical deglycosylation (Fig. 
6B). Interestingly, the fragments containing the C58S were more glycoslytated than those containing the natural 
Cys58, as previously observed (26). 
The expression level of N-terminal fragments was usually lower (>1 order of magnitude) compared with full-
length hPRL (Fig. 7C). This was not concomitant with an accumulation of hPRL fragments inside the cell (data 
not shown), suggesting that retention within the endoplasmic reticulum due to protein misfolding (27) does not 
explain the lower expression level. We also observed that the difference between expression of full-length and 
hPRL fragment was less pronounced when using freshly prepared plasmids, but this remains unexplained. Full-
length hPRL secreted into the conditioned medium was quantified using a commercial ELISA specifically 
recognizing WT hPRL (28), and its concentration was in the range of 1-2 µg/ml. None of the N-terminal 
fragments could be detected in this ELISA, because the coated antibody (mAb 5601) was shown in this study to 
map a C-terminal hPRL epitope, absent in the fragments (see Fig. 9 below). The latter were thus quantified by 
densitometric analysis of autoradiographies taking 23-kDa hPRL as the reference. To take into account the 
relative production yields of full-length hormone vs. fragments, we routinely diluted the conditioned medium 
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Fig. 7: Antiangiogenic Activity of N-Terminal Fragments on BUVEC 
A, Dose-response activity of bFGF and COS-7 conditioned medium (transfected with parental pcDNA3.1) on thymidine uptake by BUVEC. 
This experiment indicates that growth factors secreted by COS-7 cells are able to induce thymidine uptake by BUVEC. B, Antiangiogenic 
activity of N-terminal hPRL fragments containing natural Cys58 or mutated Ser58. The figure represents the effect of 10 µl of conditioned 
medium in final volume of 200 µL. C, Dose-response activity of the three N-terminal hPRL fragments 15K, 16.5K, and 17K, containing 
Cys58. The amounts of PRL hormones contained in the conditioned media used for this experiment are shown on the blot. As indicated in the 
text, conditioned medium containing hPRL was initially diluted 10- or 100-fold (panels B and C) to test similar amounts of protein for full-
length and PRL fragments. Each panel is from a single experiment performed in triplicate and is representative of at least three similar 
experiments, performed with conditioned media obtained after different transfections. D, 16.5K hPRL fragment was removed from 
conditioned medium by immunoprecipitation using a polyclonal α-hPRL antibody (right lane on the blot, Ab+). Control sample was treated 
the same way except that the antibody was omitted in the immunoprecipitation (left lane on the blot, Ab-). Immunodepleted conditioned 
medium (Ab+, 6 µl) failed to inhibit thymidine incorporation by BUVEC (100% corresponds to the stimulation obtained with 6 µl mock-
transfected conditioned medium). Bars represent averaged values from one experiment performed in triplicate. 
 
Published in: Molecular Endocrinology (2004), vol. 18, iss. 10, pp. 2522-2542 14 
Status: Postprint (Author’s version) 
Figure 7: Continued 
 
Antiangiogenic Effect of N-Terminal hPRL Fragments on Endothelial Cells 
The antiangiogenic activity of hPRL fragments secreted from COS-7 cells was determined using immortalized 
bovine umbilical vein endothelial cells (BUVEC) the growth factor-induced proliferation of which was recently 
shown to be affected by the addition of 16K rPRL (29). Preliminary studies were performed to ensure the dose-
dependent responsiveness of BUVEC to bFGF (Fig. 7A, left panel). Because hPRL fragments to be tested were 
obtained from COS-7 conditioned medium, control experiments were performed to detect any intrinsic effect of 
culture medium conditioned for 24 h in parental or mock transfected COS-7 cells. As shown on Fig. 7A (right 
panel), conditioned media stimulated the proliferation of BUVEC in a dose-dependent manner, suggesting that 
COS-7 cells secrete angiogenic factors. Identification of some of these factors was performed using a human 
angio-genesis antibody array, on which antibodies directed against 20 factors well known to play a role in 
angiogenic process, are spotted. Membrane incubated in DMEM-0.1% BSA that was used to generate 
conditioned media served as the negative control. As shown in Fig. 6C, COS-7 cells secrete at least five 
angiogenesis-related factors that could be specifically distinguished from background in this type of assay: 
bFGF, VEGF, monocyte chemotactic protein (MCP)-1 and growth-related oncogene (GRO), which are inducers 
of angiogenesis (30-33), and tissue inhibitor of metalloproteinase (TIMP)-2, which is an inhibitor of 
angiogenesis (34). The pattern of factors secreted by COS-7 cells was not affected by expression of hPRL 
fragments (data not shown). To the best of our knowledge, this is the first report identifying angiogenesis-related 
factors secreted by this cell line. With the exception of VEGF and bFGF, which were shown to stimulate 
BUVEC proliferation (29), we are not aware of any study that has investigated whether MCP-1, GRO, or TIMP-
2 affects BUVEC proliferation in vitro, or whether these cells express the cognate receptors of these factors. 
Such analyses fall beyond the scope of this study and do not question the final effect of COS-7 cell-conditioned 
medium, which is clearly stimulatory, on BUVEC (Fig. 7A). 
Although exogenous bFGF and conditioned medium had an additive effect (data not shown), we omitted adding 
bFGF in all further bioassays, because angiogenic factors present in COS-7 cell-conditioned medium were 
sufficient to induce a significant response of BUVEC (>2-fold increase in thymidine uptake over basal). Whether 
a serine was substituted for the free Cys58 or not, 10 µl of conditioned medium (in 200 µl final volume) 
containing any N-terminal hPRL fragment were sufficient to inhibit thymidine uptake induced by mock 
conditioned medium (Fig. 7B). In some experiments (Fig. 7B), but not all (Fig. 7C), hPRL exhibited a small 
inhibitory effect that never exceeded 25%, and this was not correlated to the dilution factor. Similar observations 
have been reported previously (25). We next performed dose-response analyses to better characterize the 
inhibitory effect of hPRL fragments. Due to the intrinsic angiogenic activity of conditioned media, dose-
response bioassays analyses were systematically performed using equivalent volumes of conditioned medium in 
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each well (i.e. hormone-containing conditioned media were normalized with mock transfection conditioned 
medium). As shown in Fig. 7C, the inhibitory effect of 16K-like fragments was dose dependent, with IC50 values 
in the range of 0.5-1 nM, based on fragment quantification from immunoblots. Due to the lack of real 
quantitative assay (ELISA) for the fragments, it would be misleading to attempt to predict a more precise IC50 
value, or to evaluate whether one fragment is slightly more potent than another. Finally, to definitely confirm the 
specificity of the effect induced by hPRL fragments, we removed 16.5K hPRL from conditioned medium by an 
immunodepletion experiment. As shown in Fig. 7D, there was no more inhibitory effect on BUVEC in the 
absence of hPRL fragment. In addition, because the level of thymidine uptake induced by immunodepleted 
conditioned medium (right bar) is similar to that induced by control mock-transfected medium (100% on y-
axis), this confirms that the inhibition induced by 16.5K hPRL (left bar) is actually fragment dependent and does 
not result from any loss of activity of the angiogenic factors after the immunoprecipitation procedure. 
Thus, hPRL fragments encompassing sequences 1-132 to 1-150, but not full-length PRL, are able to significantly 
inhibit growth factor-induced thymidine incorporation by BUVEC. 
N-Terminal hPRL Fragments Inhibit Growth Factor-Induced Activation of MAPK 
It was previously shown that 16K hPRL inhibition of growth factor-activated cell proliferation involves the 
inhibition of signaling cascades upstream of MAPKs (10). As shown in Fig. 8, growth factors secreted by COS-7 
cells (mock transfection-conditioned medium) induced rapid phosphorylation of MAPKs (30 min). Full-length 
hPRL did not markedly affect the level of MAPK phosphorylation. In contrast, it was inhibited by the N-terminal 
hPRL fragment (16.5K hPRL), and this occurred in a dose-dependent manner. Densitometric analysis of four 
separate experiments showed that at a 1:20 dilution, this fragment inhibits MAPK activation by more than 75%. 
N-Terminal hPRL Fragments Are Detected in hPRL-Secreting Pituitary Adenomas 
The next and final question addressed in this study relates to the potential physiological relevance of the N-
terminal hPRL fragments identified in vitro. Before analyzing human samples, we performed epitope mapping of 
several anti-hPRL monoclonal antibodies available in our laboratory, purchased commercially or obtained from 
collaborators. We used the following antigenic sequences: full-length hPRL, ∆1-9-hPRL (lacking the nine N-
terminal residues), the 15 and 16.5/ 17K N-terminal hPRL fragments generated by cathep-sin D proteolysis, and 
the 16K C-terminal hPRL fragment obtained after thrombin digestion (18). As shown in Fig. 9A, the three 
monoclonal antibodies distinguished different regions within hPRL. The mAb 6E4 recognized all the antigens 
tested, indicating its epitope lies within an overlapping sequence, identified as residues 54-132 (Fig. 9B). In 
contrast, mAb 5602 maps the N-terminal residues as it fails to detect ∆1-9-hPRL and the C-terminal 16K 
fragment generated by thrombin, whereas it detects WT hPRL and its N-terminal fragments. Finally, mAb 5601 
maps a sequence between residues 151 and 199, because it detects hPRL, ∆1-9-hPRL, and the C-terminal 16K 
fragment, but none of the N-terminal fragments. Results of the epitope mapping are summarized in Fig. 9B. 
These antibodies were used to analyze hPRL-related products present in human pituitary. PRL-secreting 
adenomas were used to increase the chances of detecting hPRL fragments. Nonsecreting pituitary adenomas 
were taken as negative controls. Pituitary lysates were immunoprecipitated using mAb 6E4 (which recognizes all 
the antigens of interest), and then immunoblots using each of the three mAbs were performed in parallel (Fig. 
9A). As would be expected, 23-kDa hPRL was the most abundant protein detected in the three PRL-secreting 
adenomas that could be analyzed, whatever the mAb used for immunoblotting (Fig. 9, middle panels). The band 
comigrating with hPRL (~25 kDa) in the nonsecreting adenoma was identified as the light chain of mAb 6E4 
used for immunoprecipitation, because it disappeared when polyclonal A549 antibody was used for 
immunoblotting (data not shown). In PRL-secreting samples, but not in nonsecreting adenoma, one faster-
migrating band was detected using mAb 5602 and mAb 6E4, but not mAb 5601. This immunoreactive band is 
clearly a hPRL-related product, because 1) it is detected using two different anti-hPRL mAbs mapping distinct 
epitopes, 2) it is not detected when mAb 6E4 is omitted in the immunoprecipitation (sample no. 3/-Ab), and 3) it 
is also absent in non-PRL-secreting adenoma. More importantly, the fact that this band is detected using mAb 
5602 but not mAb 5601 clearly indicates that it corresponds to an N-terminal, and not a C-terminal, fragment of 
hPRL. To evaluate whether this N-terminal hPRL fragment corresponds to any of those identified in vitro, one of 
the samples (no. 3) was compared with the fragments generated in vitro by cathepsin D. Right panels in Fig. 9A 
show that the N-terminal hPRL fragment identified in pituitary adenomas comigrates with the 17K hPRL, 
encompassing residues 1-150. 
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Fig. 8: Activity of N-Terminal Fragments on MAPK Signaling Pathway in BUVEC 
A, Dose-dependent inhibition of growth factor-induced activation of MAPKs by increasing amounts of conditioned medium containing 16.5 
KhPRL. The assay (final volume of 200 µl) was performed by stimulating (20 min) BUVEC with COS-7 conditioned medium as indicated 
(mock, hPRL, or dilutions of 16.5K hPRL). Full-length hPRL containing conditioned medium was diluted 10-fold, as described in the legend 
to Fig. 7. B,Bars represent the level of MAPK phosphorylation averaged from four experiments performed as described in panel A. 
Densitometric analysis was performed using Kodak 1D 2.0.2 software, and the level of activation induced by mock transfection medium 
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Fig. 9: N-Terminal hPRL Fragments Are Detected in Human Pituitaries 
A, Immunoblot analysis of various hPRL-related products using mAb5602 (fop blots), 5601 (middle blots), or 6E4 (bottom blots). Left, 
Epitope mapping of the three anti-hPRL monoclonal antibodies was performed using the following hPRL sequences: ∆1-9-hPRL (lane 1), 
full-length hPRL digested by cathepsin D (lane 2), or thrombin (lane 3). See the text and panel B for interpretation of the results. Middle, 
Three PRL-secreting (nos. 1, 2, and 3) and one nonsecreting (NS) pituitary samples were analyzed after immunoprecipitation with (+Ab) or 
without (-Ab) mAb 6E4. *, The N-terminal fragment identified in the three PRL-secreting samples. Right, The electrophoretic mobility of 
this N-terminal hPRL fragment is similar to that of 17K hPRL obtained after proteolysis of extractive hPRL by cathepsin D. B, Epitope 
mapping of the three mAbs as deduced from left portions of panel A. Sequences of full-length hPRL and N-terminal and C-terminal 
fragments are schematically represented by a horizontal line, with first and last amino acid indicated. Monoclonal 5602 is directed against the 
N terminus of hPRL (residues 1-9), whereas mAb 5601 maps a C-terminal epitope, located between residues 150 and 199. Monoclonal 6E4 




Solid tumor growth is highly dependent on angiogen-esis (35). To remain alive and to divide, cells need oxygen 
and nutrients, which are transported by the newly formed capillary networks. With the exception of specific 
physiological conditions, such as menstrual cycle, placenta formation, and tissue repair (wound healing), 
angiogenesis is a quiescent phenomenon in adults. It is believed that angiogenesis is controlled by a balance 
between antiangiogenic and proangiogenic factors, the former being predominant in normal conditions, whereas 
the balance is shifted toward the latter in tumors (36). The antiangiogenic activity of recombinant 16K hPRL has 
been widely documented in various in vitro assays performed on primary endothelial cell cultures (8,9,12), as 
well as in in vivo assays such as the classical angiogenic chick chorioallantoic membrane assay (9). Although the 
possibility was addressed that the antiangiogenic activity of recombinant 16K PRL could be due, at least in part, 
to endotoxin contamination of bacterially produced hormones used for the experiments (12), recent data obtained 
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in vivo definitely confirmed the intrinsic antiangiogenic potential of 16K PRL When human colon (25) or 
prostate (26) cancer cells transfected by expression vectors or infected by adenoviruses encoding 16K hPRL 
were xe-nografted into athymic mice, their proliferation was markedly inhibited, and this effect could not be 
mediated by endotoxin contamination because the hormone fragment was expressed by cancer cells themselves. 
Although the bioactivity of recombinant N-terminal 16K hPRL is very interesting in a pharmacological context, 
its putative physiological relevance was recently questioned by the group of Ben-Jonathan (18). Indeed, these 
authors suggested that no antiangiogenic 16K-like N-terminal fragment could be obtained from proteolysis of 
hPRL by MCF-7 microsomal pellets, even at acidic pH. In particular, they reported that hPRL is resistant to 
cathepsin D, which is the protease that was previously shown to cleave rPRL into the antiangiogenic N-terminal 
16K fragment (4). In contrast, hPRL undergoes thrombin-mediated processing at physiological pH, also leading 
to a 16K fragment, but the latter corresponds to the C-terminal sequence of PRL and is completely devoid of any 
angiostatic activity (18). We herein present data clearly showing that hPRL can be processed in vitro into 16K-
like N-terminal fragments in experimental conditions identical to those leading to the generation of rat 16K PRL. 
Obviously, the cleavage efficiency is lower compared with the rat hormone, which may be the reason why it was 
missed before. We provide several experimental observations arguing that cathepsin D is the protease involved 
in hPRL processing, the most important being that proteolytic fragments generated by mammary cell lysates or 
purified cathepsin D displayed the same N-terminal end. Cathepsin D is very abundant in human mammary 
epithelial cells (37), and its identification as the protease responsible for hPRL cleavage by breast cell extracts or 
conditioned medium is therefore not surprising. Interestingly, this protease was also shown to be responsible for 
the generation of another antiangiogenic factor, namely angiostatin, resulting from plasminogen processing (38). 
rPRL was shown to contain two cleavage sites for cathepsin D (between residues 145-146 and 148-149) (5, 39), 
both of which are homologous to cleavage sites that we identified in hPRL (residues 147-148 and 150-151). We 
demonstrate that the presence of Pro.,48 in the hPRL sequence is a limiting factor in the proteolysis, because its 
removal dramatically increases cleavage efficiency of hPRL, whereas its introduction into the rat sequence has 
the opposite effect. Two additional cleavage sites were identified in the human hormone. The one between 
residues 132 and 133 is obviously due to the presence of a Leu at position 132 instead of a Lys in the rat 
sequence. Although there is no consensus site reported for cathepsin D, these finding are in good agreement with 
the fact that the introduction of lysine and proline residues within sequences normally recognized by this 
protease is detrimental to cleavage efficiency (40). Accordingly, the proteolytic patterns obtained for ovine and 
human PRL are very similar, and distinct from that obtained with rodent PRLs (2), which correlates with the 
presence of a conserved Pro148 in the former and a conserved Lys.,32 in the latter. Finally, a fourth cleavage site 
was identified in hPRL around residue 85, although its precise location could not be determined because multiple 
fragments ending between residues 80-85 or starting between residues 85-90 were identified by mass 
spectrometry. Analysis of the three-dimensional structure of hPRL (41) clearly showed that the four cathepsin D 
sites are located in the same region of the folded protein and are indeed located very near to each other (Fig. 3D). 
Sites involving residues 147-148 and 150-151 are located in the large loop linking helices 3 and 4, which is 
floating on the side of a four-helix bundle and is presumably easily accessible to the protease. The two other sites 
(132-133 and putative 85-86) are located within helical regions, respectively: the end of helix 3 and beginning of 
helix 2. Remarkably, the addition of 0.05% Triton X-100 strongly favored proteolysis between residues 132-133, 
indicating that hPRL intrinsically contains a stretch of amino acids that is highly sensitive to ca-thepsin D. This 
is reminiscent of the previous observation that nonionic detergents markedly enhanced rPRL proteolysis by 
kallikrein, a trypsin-like serine protease (42). Under native conditions, the 132-133 proteolytic site is buried 
inside the protein (Fig. 3D) (41), which probably explains the moderate cleavage; in contrast, the detergent is 
anticipated to slightly relax hPRL folding, leading to increased accessibility of residues 132-133 and near total 
cleavage. Although these experiments were aimed only at investigating any relationships between hPRL 
conformation and proteolytic sensitivity, one may speculate that if hPRL cleavage occurs within the secretory 
pathway (27), the pattern of fragments generated could depend on its folding state. The antiangiogenic activity of 
the three 16K-like N-terminal fragments identified in this study was assessed using immortalized BUVEC, 
which were recently shown to maintain the characteristic features of endothelial cells (29). All N-terminal hPRL 
fragments produced by COS-7 cells were able to inhibit growth factor-induced thymidine incorporation by 
BUVEC. Immunodepletion experiments confirmed that the inhibitory effect is totally dependent on the presence 
of hPRL fragments, because their removal from conditioned medium fully restored the stimulatory effect 
obtained with mock-transfected medium. Whether the reduction in thymidine uptake strictly reflects an effect on 
cell proliferation, or also takes into account an increase of cell apoptosis (12,13) or other effects such as reduced 
cell adhesion, is currently under study in our laboratory. The IC50 of this inhibitory action was in good agreement 
with former studies involving bacte-rially produced 16K hPRL (residues 1-139), which was shown to inhibit the 
proliferation of bovine brain capillary endothelial cells (9) and neovascularization in the chick chorioallantoic 
membrane assay (25) with an IC50 of 1-2 nM. This demonstrates that eukaryotic cells express correctly folded 
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hPRL fragments that are at least as potent as those obtained from bacteria, confirming previous observations (25, 
43). Even more interesting is the following observation: whereas we previously noticed that some batches of 
bacterially produced 16K hPRL display weak or, at worst, no antiangiogenic activity, which remains 
unexplained, we never made such an observation with hPRL fragments secreted by COS-7. As bacterially 
produced 16K hPRL requires a denaturation-renaturation step that is not needed when using conditioned media, 
we can assume that the latter system leads to a folding process that is more reproducible. The activity of full-
length hPRL on BUVEC was either nil or slightly inhibitory, which is reminiscent of previous reports (25). 
Some cleavage may occur in COS cells, leading to the generation of small amounts of active 16K hPRL. The 
presence of a 16K-like band under reducing conditions (Fig. 6A) may argue for this hypothesis, although this 
remains speculative at this time. At the signaling level, the antiproliferative activity of 16K PRL was shown to 
involve inhibition of cascades upstream of MAPK activation (10, 11). Accordingly, the hPRL fragments 
identified in this study were able to inhibit the phosphorylation of MAPKs induced by growth factors, and this 
was also dose dependent as shown for 16.5K hPRL 
From a sequence-function point of view, the activity of 15K hPRL (1-132) is not surprising because previous 
studies showed that hPRL fragments slightly shorter (residues 1-123) (8) or longer (residues 1-139) (Ref. 9 and 
this study) displayed antiangiogenic activity. Similarly, the length of the two larger fragments (1-147 and 1-150) 
is almost the same as that of 16K rPRL (1-145), which is also antiangiogenic in the assay used in the present 
work (29). Although these data confirm that C-terminal truncation of hPRL by not more than one quarter of its 
sequence (49 amino acids) is sufficient to convert the lactogenic hormone PRL into an antiangiogenic factor, 
they also emphasize our current ignorance of the molecular features driving 16K PRL properties. Functional 
analysis of N-terminal hPRL fragments longer than 150 residues and shorter than 123 will lead to a better 
understanding of the structure-function requirements of 16K-like PRL fragments. Finally, our functional studies 
were performed using highly glycosylated hPRL fragments. The antiangiogenic properties of bacterially-
produced 16K hPRL do not support any key role for glycosylation, although we cannot exclude the possibility 
that this modification modulates the biological properties of our recombinant fragments. Testing this hypothesis 
would involve mutation of the single glycosylation site present in hPRL sequence, Asn 31 (44). 
Data currently available in the literature concerning human 16K PRL raise a paradox. Although several 
investigators published important studies describing the antiangiogenic activity of recombinant 16K hPRL in 
various models as well as certain molecular mechanisms involved (see Introduction), we are not aware of any 
report in which the existence of similar N-terminal 16K hPRL in vivo has been clearly demonstrated. A few 
reports have appeared showing that 14-18 kDa immunoreactive bands were detected when physiological fluids, 
tissue extracts, or cell culture-conditioned media were analyzed under reducing SDS-PAGE, followed by 
Western blotting experiments using polyclonal or monoclonal anti-PRL antibodies (45-49)(for a review, see Ref. 
3). However, in most of these studies, immunoreactive bands were not clearly demonstrated to be PRL related, 
and assuming they were, their identification as N-terminal PRL fragments was not assessed using appropriate 
methods (epitope-mapped mAb, N-terminal sequencing, mass spectrometry). This clearly prevents any definite 
statement regarding the relevance of antiangio-genic 16K PRL in humans, because the recent work of Ben-
Jonathan and colleagues (18) tends to suggest that these immunoreactive bands may rather correspond to C-
terminal 16K hPRL, which has no angio-static activity. In this context, our analyses of human pituitary 
adenomas provide an important information, because the use of epitope-mapped mAbs clearly identified the 
immunoreactive 16K-like band as an N-terminal hPRL fragment. Based on the comparison with the in vitro 
digestion pattern of hPRL, the fragment observed in pituitaries matches with 17K hPRL. Assuming that 
cathepsin D is the pituitary protease involved, which remains to be definitely demonstrated, this suggests that the 
150-151 site would be the preferential cleavage site in vivo. The fact that 15K and 16.5K fragments could not be 
detected is in good agreement with the observations that 1) the 132-133 site is buried inside hPRL, and 2) Pro148 
is detrimental to cleavage efficiency. Finally, because it is likely that the presence of 17K hPRL in PRL-
secreting, but not in nonsecreting, adenomas is primarily due to the fact that overexpression of hPRL in the 
former favors the detection of proteolytic fragments present in small amounts, it is probably misleading at this 
stage to link the presence of hPRL fragments with the pathological characteristics of the tumor. 
We showed that recombinant 17K hPRL displayed antiangiogenic bioactivity, even when free Cys58 is 
maintained, which is obviously the case for the 17K fragment detected in pituitaries. Therefore, our study 
certainly renews the interest in the potential relevance of antiangiogenic N-terminal PRL fragments in humans. 
Many questions remain answered, however, which prevent definitive interpretations. First, to facilitate the 
detection of fragments assumed to be present in relatively low amounts, we used PRL-secreting pituitary 
adenomas. Similar experiments should now be performed using nonpathological samples (e.g. serum, breast 
biopsies, etc), to elucidate whether the presence of hPRL N-terminal fragments is correlated with any 
pathological status or not. Such investigations will be possible once sensitive antibodies specifically directed 
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against hPRL fragments are available; this is an ongoing project in our laboratory. Second, although the 
fragment detected in pituitary adenomas matches 17K hPRL, analysis of additional samples is required to 
determine whether other fragments, possibly generated by other proteases, can be identified. Third, it is 
noteworthy that in all the experiments reported in this study, including pituitary analyses, N-terminal fragments 
were detected only when electrophoreses were performed under reducing conditions. As described in the 
Introduction, the release of 16K PRL requires proteolytic cleavage followed by reduction of the cleaved 
hormone. The molecular and cellular mechanisms that may lead to reduction of cleaved PRL in vivo are 
currently unknown, irrespective of the species considered. Understanding this process, or demonstrating that N-
terminal 16K-like fragments can be detected in human samples under nonreducing conditions, is certainly a goal 
that must be obtained in the future. 
If proteolysis and reduction occur in the mammary gland in vivo, our findings may be important for better 
understanding the role of PRL in breast carcinogenesis, which is a major goal of our group. Cathepsin D is 
expressed at a high level in breast cancer (37) and could therefore play a key role in regulating the release of 
cryptic antiangiogenic factors, e.g. 16K-like hPRL and angiostatin. In addition, recent observations suggest that 
locally produced hPRL participates in the growth of mammary tumors via an autocrine/paracrine loop (17). 
Autocrine hPRL thus might be very important in tumor progression, especially in view of its putative angiogenic 
action described in the chorioallantoic membrane assay (13). The present study suggests that the protumor action 
of hPRL in mammary tumorigenesis may be balanced by the antiangiogenic activity of N-terminal 16K-like 
hPRL fragments. Confirming the relevance of this model will require demonstrating how and where the 
molecular and cellular features leading to PRL processing into 16K PRL (protease, acidic pH, reductase, etc.) 
occur in vivo. 
MATERIALS AND METHODS 
Materials 
Reagents and Culture Media. 
 Salts were high-grade purified chemicals purchased from Sigma Chemical Co. (St. Louis, MO) or Merck 
(Darmstadt, Germany). Oligonucleotides were from Eurogentec (Liege, Belgium). Culture media, fetal calf 
serum (FCS), trypsin, and glutamine were purchased from Life Technologies, Inc. (Gaithersburg, MD). 
[3H]thymidine was purchased from Amersham (Buckinghamshire, UK).  
Proteins and Antibodies.  
For digestion studies, we used recombinant human and rat PRL produced in bacteria (pT7L-PRL vector) and 
purified as previously reported (21). Mutated hPRL and rPRL generated in this study were produced following 
exactly the same procedures. Extractive hPRL (lot 120-16-2) was a generous gift of Dr. Parlow (National 
Institute of Diabetes and Digestive and Kidney Diseases; NHPP no. 506). BSA was from Sigma. Anti-hPRL 
mAb (mAb clone 6E4) is directed against a recombinant N-terminal fragment (residues 1-139) of hPRL (14). 
6E4 mAb was found to recognize both full-length and N-terminal fragments of hPRL in Western blots. 
Polyclonal anti-hPRL antibody A569 was purchased from DAKO Corp. (Carpinteria, CA), and mAb 5601 and 
5602 are from DBC (Diagnostic Biochem Canada, Inc., London, Ontario, Canada). Extractive human liver 
cathepsin D, human plasma thrombin, and protease inhibitors were from Sigma. Antihuman cathepsin D mAb 
was a gift from Dr M. Garcia (INSERM Unit 540, France), and glycosidase (N-glycosidase F) was from New 
England Biolabs, Inc. (Beverly, MA). Monoclonal antiactive MAPK antibody (directed against 
threonine202/tyrosine204-phosphorylated MAPKs 1 and 2 (no. 9106), also referred to as antiactive Erk 1/2) was 
from Cell Signaling Technology (Beverly, MA) and polyclonal anti-MAPK1/2 antibody (no. 06-182) was from 
Upstate Biotechnology, Inc. (Lake Placid, NY). Quantification of 23-kDa hPRL secreted by COS-7 into cell-
conditioned media was performed using a hPRL-specific ELISA (Prolactin Elisa kit, DBC). Identification of 
angiogenic factors secreted by COS-7 cells was performed using human angiogenesis antibody arrays I 
purchased from RayBiotech, Inc. (Norcross, GA). For both Prolactin Elisa kit and angiogenesis array, we strictly 
followed the instructions of the manufacturers.  
Cell Lines and Human Mammary Biopsies.  
Tumor breast biopsies were obtained from three patients bearing a breast cancer, as previously described (50). 
Normal tissue adjacent to the tumor was also harvested during surgery. T-47Dco cells, an estrogen-resistant 
clone of the T-47D human breast adenocarcinoma cell line (51), were obtained from Dr. B. K. Vonderhaar 
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(National Institutes of Health, Be-thesda, MD). They were routinely cultured in RPMI 1640 supplemented with 
10% FCS, L-glutamine (2 mM), insulin (0.2 IU/ml), and antibiotics. Immortalized BUVEC were generated by 
transfecting primary cell cultures with an expression vector containing the human papillomavirus type 16 E6E7 
oncogene as previously described (29). They were routinely cultured in F12-K, 10% FCS, glutamine, and 
antibiotics. COS-7 cells were routinely cultured in DMEM, 10% FCS, glutamine, and antibiotics. 
Pituitary Adenomas.  
Pituitary samples were collected in patients undergoing surgical adenomectomy at Hδpital Foch (Paris, France). 
Both PRL-secreting and nonsecreting adenomas were made available for this study. Directly after their removal, 
pituitary samples were snap frozen until use. 
Methods 
Site-Directed Mutagenesis and Expression Plasmids. 
Expression vectors for N-terminal fragments of hPRL were generated by introducing a stop codon within the 
hPRL coding sequence subcloned into the pc-DNA3.1 vector (Invitro-gen, San Diego, CA). Site-directed 
mutagenesis was performed using the QuikChange Mutagenesis kit from Stratagene (La Jolla, CA). A stop 
codon was substituted for codons 133, 148, or 151, leading to hPRL fragments of approximately 15 kDa (1-132), 
16.5 kDa (1-147), and 17 kDa (1-150), respectively. Cognate mutants in which a serine is substituted for cysteine 
58 were also generated and are referred to as C58S analogs. The plasmid encoding the 1-139 fragment of hPRL 
was generated previously (9) and is identified in this study as 16K hPRL.  
Cleavage of hPRL by Cell Extracts, Cell-Conditioned Medium, or Purified Cathepsin D.  
Mammary cell homogenates were prepared from T-47Dco cells and pulverized breast tissues as described 
elsewhere (52). Briefly, cells were placed in 7.5 vol (wt/vol) of ice-cold 0.25 M sucrose/0.1 M Tris-HCl (pH 7.4), 
and homogenized for 30 sec using a Polytron homogenizer. The high-speed sediment was obtained by three 
successive centrifugations (10 min each) at 600 x g, 3,300 x g, and 25,000 x g. The final pellet was washed twice 
in the same buffer. 
Fifty micrograms of the 25,000 x g pellet were incubated with 20 µg hPRL for the indicated time at room 
temperature, in a final volume of 25 µl of 50 mM citrate-phosphate/75 mM NaCl (pH 3.2) (2). Heat-inactivated 
pellets (85 C, 30 min) were used as negative controls. Proteolysis was also performed using culture medium 
conditioned for 24 h with T-47Dco cells, and then acidified (pH 3.2) using HCl. Negative controls were either 
acidified nonconditioned medium or nonacidified conditioned medium (pH ~7). Various protease inhibitors were 
used at the following concentration: pepstatin A (1 µM), leupeptin (100 µM), aprotinin (0.3 µM), 
phenylmethylsulfonyl fluoride (0.2 mM), EDTA (5 mM). Proteolysis of hPRL (20 µg) by purified cathepsin D 
was performed for the indicated time, at room temperature or at 37 C, in 20 mM citrate/phosphate, 150 mM NaCI 
(pH 3 or 7) (4), using an enzyme-substrate ratio of 1:100. 
Analysis of Pituitary Adenomas.  
Pituitary adenoma samples were thawed on ice, washed several times in ice-cold PBS to remove blood and tissue 
debris, and then homogenized using a Polytron, in lysis buffer containing various protease inhibitors as 
previously described (53). Tissue homogenates were centrifuged at 10,000 x g for 10 min, and the pellet was 
discarded. For immunoprecipitation experiments, 500 µg of the tissue lysate proteins were precleared by 
incubation with protein A-sepharose beads for 2 h at 4 C. Protein A-sepharose beads were removed by brief 
centrifu-gation, and then supernatants were transferred to fresh tubes. Immunoprecipitations were performed by 
incubating lysates with 5 µl of mAb 6E4, overnight at 4 C. Immunocomplexes were collected by adding protein 
A-sepharose beads for 1 h. Immunoprecipitates were washed three times with PBS before loading on SDS-
PAGE. 
SDS-PAGE and Immunoblots.  
Analysis of PRL fragments was performed using 15-17% SDS-PAGE, in reducing and nonreducing conditions 
as indicated. Gels were either stained with Coomassie blue or immunoblotted using the following anti-hPRL 
antibodies: mAb 6E4 (2 µg/ml), polyclonal A569 (1:500 dilution), mAb 5601 or mAb 5602 (1:40 dilution). 
Antigen-antibody complexes were detected by enhanced chemiluminescence (Amersham) using an antimouse or 
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antirabbit immunoglobulin antibody conjugated to horseradish peroxidase. 
N-Terminal Sequencing of hPRL Fragments.  
hPRL fragments resulting from proteolysis by mammary cell extracts or by purified cathepsin D were separated 
by reducing SDS-PAGE and transferred onto a polyvinylidene difluoride membrane using 10 mM (3-
[cyclohexylamino]-1-propane-sulfonic acid) buffer from Sigma (pH 10.5). Bands were visualized by Ponceau 
red staining and cut out of the gel, and N-terminal sequences were determined by Edman degradation 
(Laboratory of Biochemistry, University of Liege, Liege, Belgium).  
Mass Spectrometry.  
hPRL (10 µg) [WT, or analogs referred to as ∆1-9-hPRL and G129R-hPRL (22, 28)] were digested by cathepsin 
D (3 h) in a final volume of 25 µl citrate/phosphate buffer as described above. Oxidized and reduced (100 mM 
dithiothreitol) hormone mixtures were then analyzed by mass spectrometry. Typically, 1 µl of nondi-gested or 
digested protein was mixed with 1 µl of matrix (sinapinic acid, 7.5 mg in 500 µl acetonitrile:H2O-0.1 % triflu-
oroacetic acid, 1:1 vol/vol) and 1 µl was deposited on the sample holder. Positive ions mass spectra were 
acquired on a MALDI-TOF Voyager Elite (Applied Biosystems, Framing-ham, MA) in the linear mode using 
the delayed extraction. Internal and external calibration were performed using apo-myoglobin [singly and doubly 
protonated molecules (M + H)+ and (M+2H)2+]. Uncertainties on the m/z values were determined from the 
analysis of different samples. Experiments on electroblotted (nitrocellulose) proteins (full length and fragments) 
were performed by dissolving approximately 1 mm2 of the band in the matrix solution (solvent acetone), but the 
mass spectra showed broader peaks. Thus, only the results concerning the MALDI-TOF of solutions are 
presented.  
Production of N-Terminal Fragments of hPRL in COS Cells.  
COS-7 cells were transiently transfected using lipo-fectamine plus (Invitrogen), using the following expression 
vectors: pcDNA3.1 vector (mock transfection), vectors encoding full-length hPRL, fragments encompassing 
sequences 1-132 (15K), 1-147 (16.5K), 1-150 (17K), in which the free cysteine 58 is maintained or replaced with 
a serine (C58S analogs), and finally the reference construct 1-139 (16KhPRL-C58S). 
For transfections, cells were plated in six-well plates (200,000 cells per well) in 10% FCS medium (d 1). On d 2, 
cells were transfected using 1 µg plasmid in 4 µl lipo-fectamine/6 µl plus reagent; we strictly followed the 
instructions of the manufacturer. On d 3, cells were serum starved in DMEM/0.1 % BSA, and conditioned media 
were harvested on d 4. Expression of hormones of interest was checked by Western blotting. Analytical 
deglycosylation of recombinant hPRL fragments was performed using F glycosidase by strictly following the 
instructions of the manufacturer.  
Immunodepletion of COS-7-Conditioned Media.  
Conditioned media (100 µl) containing hPRL fragment were incubated overnight at 4 C with 1 µl of polyclonal 
anti-hPRL antibody (A569). Protein A sepharose beads (20 µl) were incubated in the immunoprecipitation 
mixture for one additional hour, and then immune complexes were removed by brief centrifugation. Both the 
pellet and the supernatant were analyzed in Western blot to assess withdrawal of hPRL fragments from the 
conditioned medium. 
Biological Properties of N-Terminal hPRL Fragments 
Tritiated Thymidine Incorporation.  
Antiangiogenic properties of N-terminal hPRL fragments were determined using immortalized BUVEC, which 
were recently shown to retain a differentiated phenotype and all the characteristics of endothelial cells and to 
maintain their responsiveness to rat 16K PRL (29). Cells were serum-starved in the flasks 24 h before the assay 
and were then plated in 48-well plates (8000 cells per well; each point in triplicate) in 100 µl of F-12K 
containing 0.2% FCS. Stimulation by the hormones of interest was performed by adding 100 µl of serum-free 
DMEM containing the indicated dilution of COS-7-conditioned media, either the same day or the day after. 
Because COS-7-conditioned medium intrinsically stimulated thymidine incorporation by BUVEC, various 
dilutions of conditioned media containing PRL fragments were systematically normalized to the same volume 
using mock-transfected conditioned medium (see Results). After stimulation (16-18 h), cells were pulsed for 4 h 
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with [3H]thymidine (0.5 µCi/well), and then they were treated as previously described with minor modifications 
(25). Incorporated radioactivity was measured using a liquid scintillation counter (Wallaw 1409). 
MAPK Activation.  
BUVEC were plated in 10% FCS medium on d 1, serum starved on d 2, and stimulated on d 3 with the various 
PRLs (in serum-free medium) for 20 min. Cells were harvested and lyzed as previously described (53). Analyses 
of MAPK activation were performed using 20 µg of total cell lysates, by SDS-PAGE (12.5%) followed by 
Western blotting using antiphosphorylated MAPK antibody (dilution 1:2000). After stripping, membranes were 
reprobed using anti-MAPK antibody (dilution 1:2000). 
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